I've added Titan Pharmaceuticals (TTP) to my position trade portfolio this morning at $2.60 a share. TTP is down about 50% from it's highs this year, so there may be some tax-loss selling here and is down from it's all time high of $65.30 in September, 2000.
TTP has $1.34 a share in cash, no debt, and an impressive pipeline of drug candidates in various phases of development. At $2.60 a share, it, like the other biotechs mentioned in these blogs, has both short-term double digit appreciation potential as well as longer term home run potential. Thus, TTP joins my biotechnology list.